Tenderwize
Back to tender search

Non-exclusive agreements for Ponesimod (ATC L04AE04) - Open House

AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen·Dresden, Germany·Deadline Apr 30, 2027 · 204 days left·Open·Supplies·Framework
Sign up to saveOpen documents
Structured notice only
Original notice title

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Vereinbarungen über Arzneimittel mit dem Wirkstoff Ponesimod (ATC-Code: L04AE04) im Wege eines Open-House-Modells

30/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

30 / 100

Complexity

20 / 100

Risk factors

No minimum purchase volumes; actual demand may be very low.

Buyer may terminate the Open House if exclusive agreements are signed, potentially ending all agreements earlier.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Tender facts

Contracting authority
AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
Country
Germany
CPV
33600000 - Pharmaceutical products
Deadline
Apr 30, 2027

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Non-exclusive supply of Ponesimod (ATC L04AE04) pharmaceuticals.
  • No minimum purchase volumes; demand-driven.
Show full summary

Non-exclusive framework agreements for Ponesimod (ATC L04AE04) via an Open House model. Open to all qualified pharmaceutical entrepreneurs. No guaranteed volumes, no exclusivity. Agreement ends 30 April 2027. The notice clarifies this is not a public procurement subject to direct awards, but published for transparency.

Risks

No minimum purchase volumes; actual demand may be very low.

Buyer may terminate the Open House if exclusive agreements are signed, potentially ending all agreements earlier.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG.

Eligibility

  • Submit self-declaration on absence of exclusion grounds (§§123,124 GWB).

Administrative

  • Submit self-declaration on compliance with Russia sanctions (EU Reg. 833/2014).

Requirements may be incomplete.

Buyer

Location

Dresden, DEU

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Non-exclusive agreements for Ponesimod (ATC L04AE04) - Open House

Non-exclusive supply of pharmaceutical products containing Ponesimod. No minimum volume. Agreement concludes on an ongoing basis until 30 April 2027.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

Apr 2026 - Apr 2027

Category

Pharmaceutical products

Deadline

Deadline Apr 30, 2027

Procurement Details

Publication date
08 Mar 2026
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
162615-2026

Documents (1)

Procurement document 1

Similar tenders

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

Dec 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30